Goldsmith, Scott R.
Slade, Michael J.
Fiala, Mark
Harding, Melinda
Crees, Zachary D.
Schroeder, Mark A.
Stockerl-Goldstein, Keith
Vij, Ravi
Article History
Received: 17 June 2024
Accepted: 26 August 2024
First Online: 4 September 2024
Declarations
:
: Prior to study initiation, this study underwent review by and received approval from the Protocol Review and Monitoring Committee (Siteman Cancer Center) and the Institutional Review Board (Washington University in Saint Louis). All patients provided informed consent at time of study enrollment. The study was performed in accordance with the Declaration of Helsinki.
: SRG reports honoraria from Oncovalent, Wugen Inc, Sanofi-Genzyme, Janssen Pharmaceuticals, and Adaptive Biotechnologies and research funding from BMS. MJS reports research support from Secura Bio, Rapid Novor and Pfizer. MF reports no relevant conflicts of interest. MH reports no relevant conflicts of interest. ZDC reports research funding and honoraria from Bioline. MAS reports honoraria from Advarra, Equillium Inc, GSK, Incyte, Inmagene Bio, Novo Nordisk, and StemLine. KSG reports research support from Sanofi. RV reports research support from BMS, Takeda, and Sanofi and honoraria from BMS, Sanofi, Janssen, Pfizer, Regeneron, and Karyopharm.